Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | GPX4 | P36969 | 3/20 | 0.58 |
| ▸ | MGLL | Q99685 | 2/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31350963 | 0.86 | MAOB (0.80) | MAOBGPX4CHRNA7POLBCACNA2D1 | |
| SCHEMBL31350717 | 0.86 | MAOB (0.80) | MAOBPOLBCACNA2D1CACNA1BCACNB1 | |
| SCHEMBL5011593 | 0.84 | TSHR (0.64) | MAOBGPX4MGLL | |
| SCHEMBL5013970 | 0.83 | GPX4 (0.54) | GPX4MGLLABHD6CACNA2D1CACNA1B | |
| SCHEMBL5009483 | 0.81 | USP2 (0.70) | MAOBMGLLCACNA2D1CACNA1BCACNB1 | |
| SCHEMBL917471 | 0.79 | CACNA2D1 (0.59) | GPX4MGLLABHD6CACNA2D1CACNA1B | |
| SCHEMBL5010693 | 0.79 | RHOC (0.61) | MAOBGPX4MGLLABHD6CACNA2D1 | |
| SCHEMBL5013045 | 0.78 | ALDH1A1 (0.57) | MAOBGPX4MGLLCACNA2D1CACNA1B | |
| SCHEMBL6985975 | 0.78 | CA12 (0.71) | HSP90AA1HSD11B1POLB | |
| SCHEMBL22305103 | 0.78 | CA12 (0.71) | HSP90AA1HSD11B1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | HSP90AA1 200/4885MAOB 59/4885GPX4 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.